NASDAQ:UROVUrovant Sciences Stock Price, Forecast & News

Urovant Sciences' stock was trading at $11.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, UROV shares have decreased by 31.8% and is now trading at $7.76.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Urovant Sciences.

Urovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Urovant Sciences.

Urovant Sciences Ltd (NASDAQ:UROV) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.99) EPS for the quarter, topping the Zacks' consensus estimate of ($1.36) by $0.37.
View Urovant Sciences' earnings history.

1 Wall Street analysts have issued 1 year price targets for Urovant Sciences' shares. Their forecasts range from $28.00 to $28.00. On average, they anticipate Urovant Sciences' share price to reach $28.00 in the next year. This suggests a possible upside of 260.8% from the stock's current price.
View analysts' price targets for Urovant Sciences.

Media headlines about UROV stock have been trending positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urovant Sciences earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Urovant Sciences.

Urovant Sciences saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 857,600 shares, a decrease of 6.7% from the July 15th total of 918,900 shares. Based on an average daily trading volume, of 87,900 shares, the days-to-cover ratio is presently 9.8 days. Currently, 12.6% of the company's stock are short sold.
View Urovant Sciences' Short Interest.

Some companies that are related to Urovant Sciences include I-Mab (ARQT), Enanta Pharmaceuticals (ENTA), Stoke Therapeutics (STOK), Athenex (ATNX), Retrophin (RTRX), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Generation Bio (GBIO), Legend Biotech (PLRX), Aimmune Therapeutics (AIMT), Gossamer Bio (GOSS), BioXcel Therapeutics (BTAI), VBI Vaccines (VBIV), Repare Therapeutics (RPTX) and Morphic (MORF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Myovant Sciences (MYOV), SCYNEXIS (SCYX), VBI Vaccines (VBIV), VIVUS (VVUS), Entasis Therapeutics (ETTX), Evofem Biosciences (EVFM) and Idera Pharmaceuticals (IDRA).

(UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV."

Urovant Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (2.29%), Alyeska Investment Group L.P. (1.99%), LVW Advisors LLC (0.12%), Personal CFO Solutions LLC (0.11%), First Trust Advisors LP (0.05%) and Vigilare Wealth Management (0.03%). Company insiders that own Urovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc and Sciences Ltd Roivant.
View institutional ownership trends for Urovant Sciences.

UROV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.
View insider buying and selling activity for Urovant Sciences.

UROV stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Personal CFO Solutions LLC, Vigilare Wealth Management, LVW Advisors LLC, and First Trust Advisors LP. Company insiders that have bought Urovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc, and Sciences Ltd Roivant.
View insider buying and selling activity for Urovant Sciences.

Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of UROV stock can currently be purchased for approximately $7.76.

Urovant Sciences has a market capitalization of $241.97 million. The company earns $-146,740,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe.

The official website for Urovant Sciences is www.urovant.com.

Urovant Sciences' mailing address is 11-12 ST. JAMES S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]